Photo by lilartsy from unsplash
Atezolizumab–bevacizumab is the new standard for advanced hepatocellular carcinoma (HCC) but its impact on portal hypertension (PHT) is unknown. We aimed to identify predictive factors of acute variceal bleeding (AVB)… Click to show full abstract
Atezolizumab–bevacizumab is the new standard for advanced hepatocellular carcinoma (HCC) but its impact on portal hypertension (PHT) is unknown. We aimed to identify predictive factors of acute variceal bleeding (AVB) and to monitor PHT parameters under treatment.
Keywords:
associated bleeding;
variceal bleeding;
atezolizumab bevacizumab;
bleeding associated;
history variceal
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Liver International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!